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Abstract: 
The treatment of hyperphosphatemia remains challenging in patients receiving hemodialysis. This Phase 1b 
study assessed safety and efficacy of EOS789, a novel pan-inhibitor of phosphate transport (NaPi-2b, PiT-1, 
PiT-2) on intestinal phosphate absorption in patients receiving intermittent hemodialysis therapy. Two cross-
over, randomized order studies of identical design (ten patients each) compared daily EOS789 50 mg to placebo 
with meals and daily EOS789 100 mg vs EOS789 100 mg plus 1600 mg sevelamer with meals. Patients ate a 
controlled diet of 900 mg phosphate daily for two weeks and began EOS789 on day four. On day ten, a 
phosphate absorption testing protocol was performed during the intradialytic period. Intestinal fractional 
phosphate absorption was determined by kinetic modeling of serum data following oral and intravenous doses 
of 33Phosphate (33P). The results demonstrated no study drug related serious adverse events. Fractional 
phosphate absorption was 0.53 (95% confidence interval: 0.39,0.67) for placebo vs. 0.49 (0.35,0.63) for 50 mg 
EOS789; and 0.40 (0.29,0.50) for 100 mg EOS789 vs. 0.36 (0.26,0.47) for 100 mg EOS789 plus 1600 mg 
sevelamer (all not significantly different). The fractional phosphate absorption trended lower in six patients who 
completed both studies with EOS789 100 mg compared with placebo. Thus, in this Phase 1b study, EOS789 
was safe and well tolerated. Importantly, the use of 33P as a sensitive and direct measure of intestinal phosphate 
absorption allows specific testing of drug efficacy. The effectiveness of EOS789 needs to be evaluated in future 
Phase 2 and Phase 3 studies. 
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CONCLUSION:
EOS789, a broad-spectrum inhibitor of phosphate transport, is safe 
with an indication of efficacy in a Phase 1b randomized cross-over 
trial in hemodialysis patients.
EOS789 was safe and well-tolerated in doses 
up to 100 mg thrice daily. Further studies are 
required to establish efficacy and optimize dose 
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Intestinal P absorption by 33P radiotracer
Two RCT crossover studies




No study drug related SAEs
Results
33P radiotracer can be used 
for direct measurement of  
intestinal absorption in 
hemodialysis patients 
Introduction: 
Hyperphosphatemia is associated with increased morbidity and mortality in patients with both 
chronic kidney disease (CKD) and with end-stage kidney disease (ESKD)1-3. Furthermore, elevated 
phosphorus/phosphate (P) directly induces vascular calcification and secondary hyperparathyroidism4 
and indirectly induces left ventricular hypertrophy mediated through fibroblast growth factor 23 
(FGF23)5-7. These adverse effects of hyperphosphatemia have led to the administration of P binders 
to reduce serum P levels in patients undergoing dialysis. The Dialysis Outcomes and Practice 
Patterns Study indicates 88% of patients undergoing dialysis are prescribed binders, and yet the 
average P level remains above target 8. Furthermore, in this same study, 45% of patients admitted to 
non-adherence of the binders 9. Thus, alternative treatments to lower P are needed. 
In patients with CKD, dietary P intake impacts serum P level, and P bioavailability varies by 
food source10-12. Although 24-hour urine studies have been considered surrogates of intestinal P 
absorption, we have shown from a secondary analysis of metabolic balance studies in CKD patients 
consuming a consistent controlled P diet that 24-hour urine P was unrelated to net intestinal P 
absorption from balance. Rather, 24-hour urine P was inversely related to whole-body P balance13. 
Thus, even in moderate CKD patients who still produce urine, the use of 24-hour urine P as a 
biomarker of intestinal P absorption may not be accurate. In patients undergoing dialysis, where urine 
output is negligible, serum P has been used to study drug efficacy. However, the removal of P with 
dialysis, the rebound of serum P post dialysis, diurnal variability of serum P levels, and bone turnover 
with uptake and release of P vary among patients and thus serum P is nonspecific in relation to 
intestinal absorption. To overcome these limitations, we adaptated the direct and sensitive gold-
standard dual isotopic tracer that utilized both 32P and 33P isotopes14, 15. Here, we used oral and IV 
doses of 33P radiotracer to assess intestinal fractional P absorption after an oral dose, followed by 
compartmental changes and total body removal with the IV dose.  This approach parallels our 
previous work in intestinal calcium absorption in patients with CKD16.    
Intestinal P absorption includes both active (transcellular) and passive (paracellular) 
absorption. As recently reviewed, the major known and most studied intestinal P transporter is the 
sodium-P cotransporter NaPi-2b (SLC34) 17. Studies in mice with CKD show that knocking out this 
transporter reduces hyperphosphatemia and bone loss18, 19.  However, a NaPi2b inhibitor, ASP3325, 
did not show efficacy in inhibiting phosphrous transport in human healthy subjects and in patients 
undergoing dialysis20.  Recent studies have also demonstrated the presence of both PiT-1 and PiT-2 
(SLC20) in intestinal segments in humans21, but their relative contribution to active P transport is 
unclear22, 23. Thus, it is possible that inhibition of PiT-1/2 may be required to significantly reduce active 
intestinal P transport in humans compared to inhibition of NaPi-2b alone. 
EOS789 is a novel inhibitor of NaPi-2b, PiT-1, and PiT-2.  EOS78924 inhibited sodium-
dependent P uptake in in vitro cultured cells and inhibited sodium-dependent P uptake in brush 
border membrane vesicles prepared from rat small intestine. EOS789 inhibited intestinal P absorption 
in healthy rats in a dose dependent manner. Further, EOS789 given to hyperphosphatemic rats, 
reduced serum concentrations of P, FGF23 and intact PTH in a dose dependent manner24. In Phase 
1 healthy human volunteer studies, there was a dose dependent increase in P content of feces with 
doses administered safety up to 100 mg TID (Hisada et al, ASN FR-PO144, 2019). Side effects 
included gastrointestinal symptoms, and a reversible skin rash observed only at the highest dose. 
The observed efficacy in the healthy volunteer study provided the basis for testing in patients 
undergoing hemodialysis. The starting dose for this study of 50 mg three times per day (TID) was 
selected to provide a slightly lower dose than the maximal safe dose with pharmacodynamic activity 
data in the healthy volunteer study. 
We report the use of this dual 33P radiotracer method in two Phase 1b, random-order, cross-
over studies of identical design conducted in 10 patients per study with hyperphosphatemia receiving 
hemodialysis thrice weekly (Figure 1).  The first study (Study 1) was a double-blinded study 
comparing 50 mg EOS789, a pan-phosphate transport inhibitor, to placebo TID with meals. The 
second study (Study 2) was unblinded and compared EOS789 100 mg TID with, versus without, 
sevelamer carbonate 1600 mg TID with meals. The primary end points were the safety of EOS789, 
and the drug’s efficacy in reducing intestinal P absorption measured directly with a radioisotope.     
Results:  
Safety Analyses: 
The number of patients who reported at least one AE, and the number of events for all four arms 
is presented in Table 1.  Serious Adverse Events (SAEs) occurred in 1 of 13 patients (7.7%, 2 
events: lung abscess and osteomyelitis) treated with EOS789 50 mg TID and in 2 of 12 patients 
(16.7%, 3 events: cellulitis and heat stroke in 1 patient, and bacteremia in 1 patient) treated with 
EOS789 100 mg TID. AEs leading to discontinuation of study drug occurred in 1 of 13 patients (7.7%, 
1 event: gastroenteritis) treated with EOS789 50 mg TID and in 1 of 12 patients (8.3%, 1 event: 
bacteremia) treated with EOS789 100 mg TID. The principle investigator (blinded to allocation) 
evaluated the available clinical information and determined unlikely causal relationship with study 
drug for all SAEs. A detailed list of AEs by organ system is provided in Supplemental Table 1. 
Efficacy analyses:   
The demographics and baseline laboratory tests are shown in Table 2 and the patient 
allocation information in Supplemental Figure 1. Six patients completed both Study 1 and Study 2. 
The mean compliance rate of placebo/EOS789 treatments was a pill count of 95% to 97%. The 
percentage of patients with treatment compliance by pill count ≥ 80% in each group was 91.7% to 
100.0%. The pharmacokinetic levels for EOS789 as a composite and by dose are shown in Figure 
2, and individual patient curves in supplemental Figure 2. The Cmax and the AUC were 
estimated with the plasma concentration profile which was conducted for the period of 3 doses over 
24 hours,  corresponding to dosing at 0, 4 and 8 hours. The Cmax for 50 mg TID, 100 mg TID, and 
100 mg TID + sevelamer carbonate was 76.2 ± 24.2, 121 ± 20.3, and 188 ± 23.7 ng/mL, 
respectively; and mean ± SD of AUC from time 0 to 24 hours was 1190 ± 387, 1900 ± 342, and 
2560 ± 119 h*ng/mL, respectively. The drug is highly protein bound (99.6% in humans), and thus, 
the removal rate with dialysis was negligible.  
Mean [SEM] intestinal fractional P absorption in Study 1 for placebo was 0.53 [0.06] (95%CI: 
0.39, 0.67) and for EOS789 50 mg TID was 0.49 [0.06] (95%CI: 0.35, 0.63) (difference of -0.04, 
95%CI: -0.18, 0.10, p=0.52, Figure 3A); and in Study 2 was 0.40 [0.05] (95%CI: 0.29, 0.50) for 
EOS789 100 mg TID and 0.36 [0.05] (95%CI: 0.26, 0.47) for EOS789 100 mg TID + sevelamer 
carbonate (difference of -0.03, 95%CI: -0.13, 0.06, p=0.45, Figure 3B). Cross-over period and 
randomized order effects were tested in the ANOVA models and were not significant for either Study 
1 or Study 2. The addition of potential confounders as covariates of peak plasma P, pre-dialysis 
plasma P, or pre-post dialysis plasma P drop did not alter the non-significant results. In a pre-planned 
secondary analysis of the N=6 patients who completed both Study 1 and Study 2, intestinal fractional 
P absorption was lower with EOS789 100 mg (0.44 [0.07]; 95%CI: 0.29, 0.59) compared with placebo 
(0.63 [0.07]; 95%CI: 0.48, 0.79) (difference of -0.19, 95%CI: -0.365, -0.03, nominal p=0.028) and 
trended lower compared with EOS789 50 mg (0.55 [0.07]; 95%CI: 0.40, 0.70) (difference of -0.11 
95%CI: -0.28, 0.05, p=0.165) (Figure 4). There was a strong correlation between the 1,25(OH)2-
vitamin D levels and intestinal fractional P absorption in the patients from Study 1 in the placebo arm 
(n = 9 due to insufficient blood sample in one patient, r2 = 0.64, p = 0.009; Supplemental Figure 3A). 
However, there was not a significant relationship in the 1,25(OH)2-vitamin D levels and fractional P 
absorption when all treatments were considered (n = 19, r2 = 0.16, p  = 0.09; Supplemental Figure 
3B) 
The mean change [SD] from baseline to Day 13 in serum P following treatment was −1.00 
mg/dL [1.31] with placebo vs. −1.28 mg/dL [1.21] with EOS789 50 mg TID in Study 1 (Difference of 
-0.32; 95% CI: -1.03, 0.38, p = 0.32), and −1.46 mg/dL [1.34] with EOS789 100 mg TID vs. −2.71
mg/dL [1.73] with EOS789 100 mg TID + sevelamer carbonate in Study 2 (Difference of -1.47; 
95%CI -2.07, -0.87, p< 0.001). The majority of study participants did not have daily fecal excretion 
during the inpatient stay limiting our evaluation of fecal data over the short two day collection 
period. However, available data show that accumulated fecal excretion of P (N=8) trended lower in 
EOS789 50 mg TID treated subjects compared to placebo by −279 mg/day (95%CI: −883, 324; 
mean [SE]: 581[200] and 860[183] mg/d, respectively, p=0.33). In Study 2, accumulated fecal 
excretion of P (N=6) trended lower in EOS789 100 mg TID + sevelamer carbonate compared to 
EOS7789 100 mg alone by −226 mg/day (95%CI: −549, 97; mean[SE]: 552[92] and 777[112] mg/d, 
respectively, p=0.15). Urine collection was too sparse to evaluate or include in the absorption 
model. In Study 1, there were no significant differences in serum P, corrected Ca, Ca x P, intact 
PTH, or C-terminal FGF23. In Study 2, EOS789 100 mg TID + sevelamer carbonate lowered serum 
P, Ca x P, and serum intact PTH compared with EOS789 100 mg TID alone (p<0.05) 
(Supplemental Table 2). 
Discussion: 
EOS789, a NaPi-2b, PiT-1, and PiT-2 inhibitor, was shown to be safe and well tolerated in 
patients undergoing hemodialysis. We elected to start at the lowest possible dose of 50 mg TID in this 
Phase1b study given the primary end point was safety, and patients undergoing dialysis have many 
co-morbidities. That dose was not efficacious in reducing intestinal P absorption compared to 
placebo. However, a pre-planned secondary analysis of the six patients who were enrolled in both 
studies showed a nominally significant reduction in intestinal P absorption with EOS789 100 mg TID 
compared to placebo. Additional studies are required at higher doses of EOS789 and/or more 
patients to determine efficacy. 
Interestingly, intestinal P absorption in patients receiving 100 mg TID of EOS789 without, 
versus with sevelamer at 1600 mg TID were not different. However, serum P was lower at day 13, 
and fecal P was greater with the addition of sevelamer.  Unfortunately, we did not have a treatment 
arm with sevelamer alone, making interpretation of this finding difficult. In humans, the relative 
proportion of passive absorption versus active transport is difficult to study. Larsson et al. found that a 
NaPi-2b inhibitor, ASP3325, was effective in lowering P in rodents, but did not alter urine or fecal P 
excretion in healthy individuals20. In contrast, EOS789 in Phase 1 studies in healthy individuals 
increased fecal P by 13.4 to 209 mg/day in doses investigated (Hisada et al, ASN FR-PO144, 2019, 
unpublished). This would suggest that pan-inhibition of NaPi-2b, PiT-1, and PiT-2 may be required. 
Paracellular absorption is also important in humans, as tenapanor, a gastrointestinal 
sodium/hydrogen exchanger 3 (NHE3) inhibitor which decreases paracellular P permeability and thus 
absorption 25, lowered serum P in dialysis patients26. Interestingly, we did find a relationship between 
1,25(OH)2D levels and intestinal P absorption in the placebo arm, but not when all treatments were 
considered.  However, given the inter-individual variability in intestinal P absorption, and that most 
patients achieved normal levels with pharmacologic therapy of doxercalciferol, the role of vitamin D in 
intestinal transport assessed with this methodology needs to be tested by prospectively assessing 
absorption before and after calcitriol administration.    
In the present study we demonstrate that the use of 33P radiotracer can be used in patients on 
hemodialysis to directly measure intestinal P absorption. Isotope techniques were used frequently in 
the 1960s and 70s27, but have been sparsely used since due to challenges including expense, 
subject burden, and/or need for radioactivity exposure. An accepted gold standard dual-isotope 
method for fractional P absorption requires use of both the low-energy beta emitter, 33P, plus the 
high-energy 32P, which is more hazardous. We adapted our previously published 45calcium 
radiotracer technique to 33P, where we mimicked a dual-isotope method using 33P for both the oral 
dose and the IV dose, staggering these by a day to differentiate between the oral and IV 
administrations in the specimens. After the measurement of the 33P in serum following the oral 
administration, any residual 33P prior to the IV 33P administration is included in the model.  All 
subsequent radioactivity counts in samples are considered to be from the IV 33P administration. This 
approach is possible because after one day, the detectable oral 33P dose remaining is an order of 
magnitude lower than the radioactivity counts assessed following the IV 33P dose (Figure 5).  By 
containing the absorption test during the interdialytic period, we were able to account for IV clearance 
of the isotope for each subject individually to estimate intestinal fractional P absorption, despite 
differences in dialysis among patients and potential dialytic clearance.   
A rigorous “gold-standard dual isotope study” would administer two isotopes on the same day 
and both isotopes would be measured from the same samples.  Farrington et al14 used oral 32P and 
IV 33P in patients with severe non-dialysis CKD (creatinine clearance of 6 ± 4 ml/min), controls, and 
transplant recipients.  They found that an intial rapid phase of intestinal absorption was completed by 
around 3 hours, but absorption continued at a slower rate through 7 ½ hours, and that fractional 
absorption calculated from data through 24 hours was not different than calculations based on data 
only through 7 ½ hours. As shown in our Figure 5, we allowed for 25 hours between the oral and IV 
doses of 33P, which based on the results reported by Farrington et al14, the absorption of the oral 33P 
isotope should have been completed. And, although the oral 33P radioactivity counts were not back to 
baseline (similar to observations by Farrington), as described above, they were >10-fold less than the 
radioactivity counts following the IV 33P dose.  Thus, this order of magnitude difference between oral 
and IV 33P radioactivity counts and the minimal additional absorption between 7 ½ and 24 hours, as 
described by Farrington, allows for the use of this single-isotope modified absoption testing protocol.  
Further, the gold-standard dual-istope method for P requires the use of 32P, which is more hazardous 
and less acceptable now for human use, so even a validation study of our single isotope method 
against the dual-isotope method would be a challenge in regard to accepatable risk to patients. 
Wiegmann and Kaye15 performed balance studies in hemodialysis patients using a single isotope 
(32P) given two weeks apart, first by IV, then by oral administration. In this study, 45Calcium was also 
used which precluded use of concurrent, administration of 33P, which have similar engery peaks by 
scintillation counting. We surmise that the long duration between the IV and oral administrations was 
because the more hazardous 32P was used; thus, the longer duration spaced out the radioactivity 
exposures to the patients. However, this long duration between IV and oral isotope administrations is 
not ideal for assessing fractional absorption, because of lack of steady-state over that time due to a 
variety of predicatble as well as unknown changing conditions – e.g. dialytic removal and flutuating 
dietary intake.  
A strength of our study was the controlled diet designed to provide consistent amounts of 
macronutrients and key micronutrients daily and evenly by meal. Our rotating 3-day cycle menu 
introduced some variation which is a limitation in contrast to providing the exact same meals every 
day. However, use of cycle-menus are standard in controlled feeding and balance studies in humans 
to enhance participant recruitment and retention into these already-burdensome studies. The menus 
were designed to be consistent in macronutrients and key micronutrient and even similar in proportion 
of animal and plant sources of protein, which can affect P bioavailablity. Additionally, the same menu 
was given during the P absorption study in the CRC on both the oral 33P and IV 33P dose days. 
Additional limitations of our study was the sparse stool collections over the two-day inpatient period 
that precluded use of stool data in the kinetic model or measurement of stool P as a secondary 
measure of absorption, and that the two-day absorption test period is not long enough for estimation 
of the slow turnover pools in the kinetic model (e.g. bone turnover) – which would require a longer full 
metabolic balance study.   
It is important to emphasize the multiple variables affecting serum P in patients on dialysis. 
While many dialysis patients are anuric, some patients, especially those on peritoneal dialysis retain 
residual renal function. Wang et al. demonstrated that anuric patients undergoing peritoneal dialysis 
had elevated serum P levels nearly twice as often as patients without residual renal function28. The 
removal of P with dialysis varies considerably and is affected by blood flow, dialysis duration, the pre-
dialysis serum P, PTH level and ultrafiltration volume29, 30. Traditional thrice weekly hemodialysis 
leads to a rebound of serum P from extracellular stores, including bone, after dialysis but the timing of 
that rebound varies31-33. Recent studies demonstrated hemodiafiltration, compared to hemodialysis, 
leads to greater removal of P due to the expanded ultrafiltration34 and nocturnal, compared to 
intermittent dialysis removes more P35. Increased bicarbonate dialysate may impact P removal36, and 
flux of P out of bone may also vary depending on the bone turnover29. Finally, even in dialysis 
patients there is diurnal variation in serum P levels, complicating pre-dialysis measures across 
multiple dialysis shifts20. Thus, studying P homeostasis in dialysis patients is very difficult and direct 
assessment using oral and IV radiotracer 33P as demonstrated in the present study is a way to 
confirm true drug efficacy at the intended target site of the intestine.   
In summary, we present promising data for safety of a novel pan- inhibitor of 
sodium/phosphate co-transport in patients undergoing hemodialysis using a novel technique of oral 
and intravenous of 33P radiotracer kinetic modeling. Future studies are required to determine efficacy 
of higher doses of EOS789, the role of EOS789 with diets of differing P content, and the potential 
mechanisms by which intestinal P absorption varies in patients with CKD. In addition, long term safety 
studies are needed to assess any adverse effects of pan-phosphate transporter inhibition. 
Materials and Methods: 
Study design: Two Phase 1b, random-order, cross-over studies of identical design were 
conducted in patients with hyperphosphatemia receiving hemodialysis thrice weekly (NCT02965053; 
Indiana University Institutional Review Board approval 1608100544). The first study (Study 1) was a 
double-blinded study comparing EOS789 50 mg to placebo TID with meals. The second study (Study 
2) was unblinded and compared EOS789 100 mg TID with versus without sevelamer carbonate 1600
mg TID with meals. Twelve to 14 patients were recruited in each study to have a final number of 10 
patients per study with all measurements from both treatments available for efficacy analyses. The 
first patient was consented in May 2017, and the last intervention for study 2 was July 2018.  See 
Supplemental Figure 1 for enrollment information. The primary endpoint for both study 1 and study 2 
was safety and determined by adverse events and safety labs. Secondary efficacy endpoints for both 
studies were differences between the two treatments in 1) intestinal fractional P absorption, 2) serum 
P, serum Ca, serum Ca × P, serum intact PTH, and serum C-terminal FGF23 at Day 13, and 3) 
accumulated fecal excretion of P from Day 11 to 13. Plasma concentration and pharmacokinetics of 
EOS789 were determined in the first cross-over session of each study prior to the 33P dosing (n = 6). 
The study schema is shown in Figure 1.   
The complete list of inclusion and exclusion criteria are detailed in Supplemental Table 3. In 
brief, patients were 18 years or older, on P binders, and on thrice weekly hemodialysis for at least 3 
months with no change in dialysis prescription or CKD-MBD drug treatments in the preceding 4 
weeks. After informed consent, patients stopped their P binders for 15-19 days and underwent 
screening laboratory tests pre-dialysis. Those with serum P ≥ 7.0 mg/dL were eligible for the study 
and on Day 1 began the controlled study diet of 900 mg/d P. The study diet was designed by a 
registered dietitian bionutritionist using ProNutra software (Viocare, Inc., Princeton, NJ). The diet 
consisted of a 3-day cycle menu, with assurance that patients had the same diet during the oral and 
IV 33P administration during each arm of each study while in the CRC.  Meal composites were 
prepared, homogenized, and sent for analysis of minerals (Ca, P, Mg, Na, K) by inductively coupled 
plasma-optical emission spectrometry (ICP-OES) and protein content by the Dumas method 
(Covance Laboratories, Madison, WI).  Nutrient content of for each meal of the 3-day cycle menu is in 
Supplemental Table 4. All study meals were prepared in a metabolic kitchen, with ingredients 
weighed to 0.1g accuracy and precision. For Days 1-9, patients received their study diets as pack-out 
meals. Diet began on Day 1, and on Day 4, subjects underwent pre-randomization visit with baseline 
blood biochemistries. Those with serum P < 10 mg/dL and increase in serum P by ≥ 0.5 mg/dL were 
randomized 1:1 by the Indiana University Investigational Pharmacy to receive study drug (EOS789 50 
mg or placebo in Study 1, and EOS789 100 mg with or without 1600 mg sevelamer carbonate in 
Study 2). Patients continued the diet for a total of 13-14 days and study drug for 10 days.   
After 7 days of study drug, on Day 10 of each treatment, patients were admitted to the Indiana 
University Clinical Research Center (CRC) for pharmacokinetic testing. On Day 11, blood was drawn 
and patients underwent their regular hemodialysis treatment. On returning to the CRC, they began 
the 33P absorption test protocol (see below). On Day 13, patients had their final 33P blood drawn pre-
dialysis and were discharged home. On Day 28, subjects had a follow-up safety visit to either begin 
the second sequential treatment or complete the study.  Thus, wash out between the two arms was 
28 days, chosen to account for more than 5 half-lives of the study drug.   Pill counts were used to 
assess study drug compliance, and uneaten diet was estimated from returned checklists or review of 
the meal tray when in the CRC. Electrocardiograms were done in both studies, and echocardiography 
in Study 2 for safety purposes. No changes in dialysis prescription (other than ultrafiltration) occurred 
during each study. Adverse events were monitored by a safety committee. 
Biochemistries: Serum Ca, P and other safety biochemistries were analyzed in the Indiana 
University Pathology Laboratories. Intact PTH was measured by Alpco Intact PTH ELISA (1-84), and 
C-terminal FGF23 was measured by Quidel Corporation human FGF-23 (C-terminal) ELISA Kit.
1,25(OH)2-vitamin D levels were measured at baseline of each period by Extraction/Liquid 
Chromatography-Tandem Mass Spectrometry (LC-MS/MS) at Mayo Clinic, Rochester, MN. 
Intestinal Fractional P Absorption (Figure 5 and Supplemental Figure 4): Intestinal 
fractional P absorption was determined from oral and IV administration of 33P radiotracer. The 
method used mimicked the double-isotope method using a single isotope by administering the oral 
isotope on the first day and the IV isotope on the second day. On Day 11 after dialysis, baseline 
blood was drawn, then 10 microcurie (μCi) 33P (33P-orthophosphate, Perkin Elmer) was 
administered orally with lunch (meal contained ~300 mg P) followed by 6 hours of blood draws 
(time points: 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 6 hours post-administration of 33P). 
Patients were asked to void urine and defecate prior to the oral administration of 33P. The 24-hour 
post-oral 33P blood sample was obtained on Day 12 before the IV 33P administration. On Day 12, 10 
μCi 33P was then given by IV (1 hour after lunch, or 25 hours after oral 33P), after a baseline blood 
draw (time point: 0, prior to IV 33P), followed by 6 hours of blood draws at time points: 15 and 30 
minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 6 hours post-administration of IV 33P). On Day 13, the final, 
24-hour post-IV dose blood sample for 33P was collected. During the 48-hour inpatient study, all
feces and urine (if patient was not anuric) was collected. Fecal samples were homogenized, ashed 
in a muffle furnace (Thermolyne Sybron Type 30400, Dubuque, IA, USA), and diluted with 2% nitric 
acid for mineral analysis (Optima 4300DV, Perkin Elmer, Shelton, CT)37. Urine samples were 
acidified with 1% (volume/volume) concentrated hydrogen chloride (HCl) at the time of aliquoting, 
and diluted with 2% nitric acid for mineral analysis by ICP-OES. 33P activity was measured in 
serum, urine, and feces by liquid scintillation counting (Tri-Carb 2910 TR Liquid Scintillation 
Analyzer, Perkin Elmer, Waltham, MA). 33P tracer data in serum (% of dose/mL) and total P in 
serum (mg/dL) were used for kinetic modeling to determine fractional P absorption. Urine and fecal 
33P and total P data were obtained in some patients over the 48 hours but were too sparse to be 
included in the modeling results. The 33P data were analyzed by compartmental modelling using a 
general equation-solving software (WinSAAM) with the percent absorption calculated as the 
fraction of P moving into blood vs. moving down the intestinal tract (Supplemental Figure 4).   The 
model structure was determined from previous studies in healthy humans38; an example of the 
serum 33P curves following oral and intravenous 33P administration is shown in Figure 5.  
Statistical Analyses: This was a pilot study with a goal of having 10 patients complete both 
arms in each study to assess safety and efficacy of phosphorus absorption, with 12-14 patients 
recruited to ensure 10 completions.  This sample size provides 80% power to detect adverse events 
(AEs) of true proportion of 16.7%. The safety population was defined as the 14 (Study 1) and 12 
(Study 2) patients who received any study treatment and had at least one safety assessment visit. 
Safety was determined by the summary of AEs, vital signs, clinical laboratory tests, ECGs, and 
echocardiograms. AEs were summarized by Medical Dictionary for Regulatory Activities (MedDRA) 
system.  Drug relatedness was assessed by the Principal Investigator (blinded to treatment 
allocation) after reviewing all data available from each event. Efficacy analyses were conducted only 
on the patients that had complete data set (n=10 for each study). Demographic and baseline 
characteristics, and exposure to study treatment were summarized by treatment for each study. The 
efficacy outcomes of interest were analyzed using an analysis of variance (ANOVA) mixed model for 
crossover designs by SAS software (v9.4 Cary, NC) with fixed effects for order, period, and 
treatment, and random effects for subject nested within order.  In exploratory analyses, peak plasma 
P, pre-dialysis P, and pre-post dialysis drop in plasma P were examined as covariates in the ANOVA 
models of treatment differences in intestinal fractional P absorption. In a secondary analysis, data 
from subjects who completed both Study 1 and Study 2 (N=6) were analyzed for differences in 
intestinal fractional P absorption among placebo, 50 mg EOS789, and 100 mg EOS789 by an 
ANOVA mixed model with fixed effects for treatment and random effects for subject. Two-sided 
statistical significance was set at α=0.05. 
The pharmacokinetic analyses calculated individual and mean plasma EOS789 concentration 
versus time data were tabulated and plotted by dose level. The plasma PK of EOS789 was 
summarized by estimating total exposure (area under the curve [AUC]), maximum concentration 
(Cmax). Calculation of EOS789 removal ratio during a single hemodialysis session was performed. 
All plasma samples for the PK analyses were collected only for the first treatment arm in each study. 
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Table 1:  Adverse Events (AE) 
Arm Number 
(percent) of 
patients with at 




Number (percent) of 
patients with AE 
considered related to 
EOS789 
Number of AE events 
considered possibly 




7 (53.8%) 9 events 2 (15.4%) 2 events (restless legs 















mg tid + 
sevelamer 
carbonate 
1600 mg tid 
(n=11) 
7 (63.6%) 9 events 4 (36.4%) 4 events (nausea, 
hypercalcemia, 
hyponatremia, bundle 
branch block right) 
 
  
Table 2  Subject Demographics and Baseline Biochemistries  
 Study 1 (n = 10) Study 2 (n = 10) 
Age, yr 
52.3 ± 10.0 
(median 52.0,  
range 41-69) 
56.7 ± 14.3 
(median 55.0,  
range 38-85) 
Age Groups, n (%)   
30  - 39 0 1 (10.0%) 
40 – 49 4 (40.0%) 3 (30.0%) 
50 – 59 4 (40.0%) 2 (20.0%) 
60 – 69 2 (20.0%) 2 (20.0%) 
> 70 0 2 (20.0%) 
Sex, n (%)    
Male 4 (40.0%) 2 (20.0%) 
Female 6 (60.0%) 8 (80.0%) 
Ethnicity, n (%) 
 
  
Non-Hispanic or Latino 10 (100.0%) 10 (100.0%) 
Race, n (%)   
Black or African American 8 (80.0%) 9 (90.0%) 
White 2 (20.0%) 1 (10.0%) 
BMI, kg/m2 




32.0 ± 9.5 
(median 30.2,  
range 20.6-
52.5) 
Tobacco use history, n (%)   
Never 5 (50.0%) 5 (50.0%) 
Current 3 (30.0%) 3 (30.0%) 
Previous 2 (20.0%) 2 (20.0%) 
Dialysis Vintage, yr ± SD 5.24 ± 4.37 3.48 ± 2.27 
On VDRA, n (%) 9 (90.0%) 9 (90.0%) 
On Calcimimetic, n (%) 3 (30.0%) 1 (10.0%) 
Serum P, mg/dL   
Screening  5.4 ± 1.3 5.8 ± 1.1 
After binder washout  6.8 ± 1.7 8.0 ± 2.1 
   After 3 days diet, Baseline  
    (pre-drug treatment)- first arm 6.8 ± 1.2 7.2 ± 1.8 
Baseline Serum Ca, mg/dL 8.9± 0.98 9.5 ± 0.9 
Baseline Serum intact PTH, pg/mL 
 
529 ± 604  
(median 398) 
354 ± 228 
(median 339) 
Baseline C-terminal FGF23 (RU/mL) 37,085 ± 40,633 
(median 15,781) 
30,888 ± 40,794 
(median 14,941) 
Baseline 1,25 vitamin D, pg/mL 
Reference range males-18-64 pg/mL 
and females 18-78 pg/L 
27.1 ± 13.9* 
Range (< 8 to 51) 
35.7 ± 21* 
Range (< 8 to 83) 
 Values are mean ± SD unless otherwise indicated. 
VDRA = Vitamin D receptor analogue 
* for values < 8, the number 8 was used to calculate the mean ± SD  
Figure Legends: 
Figure 1: Schematic of study design.   
Each study consisted of two sequences (arms) of 13-14 days duration with a two week wash out 
between sequences.  During the sequence, subjects had study diet for the entire duration and study 
drug began on Day 4.  The subjects were hospitalized in the Clinical Research Center on Day 9 (first 
sequence for PK) or Day 10 (second sequence) of each study.  Patients underwent hemodialysis 
prior to admission, and as the final event during the admission such that all of 33P studies were done 
between dialysis treatments. 
 
Figure 2: Pharmacokinetic (PK) analyses of EOS789. 
Mean ± SD plasma EOS789 concentration at steady state (on Day 10). PK sampling points were pre-
morning dose, and 1, 2, 4, 6, 8, 12, 24 hours post-dose. Doses were given at 0, 4, and 8 hours. Only 
the first sequence was used for the PK sampling with n = 5 to 7 per group.  Individual PK curves for 
each dose are shown in Supplemental Figure 2.  
 
Figure 3: Intestinal fractional P absorption by 33P.  
Fractional P absorption in individual patients in Study 1 (A: comparing placebo versus EOS789 50 mg 
TID with meals) and Study 2 (B: comparing EOS789 100 mg versus EOS789 100 mg with sevelamer 
TID with meals). Each line represents one patient, EOS789-50= EOS789 50 mg TID, EOS789-100 = 
EOS789 100 mg TID, EOS789-100 + Sev = 100 mg EOS789 + 1600 mg sevelamer TID.  P = 
phosphorus/phosphate.  
 
Figure 4: Dose efficacy of EOS789 in intestinal fractional P absorption.  
In a planned secondary analysis, data from the six patients who completed both studies were 
analyzed to generate a dose response comparing placebo, EOS789-50 = 50 mg TID, and EOS789-
100 = EOS789 100 mg TID. There was a significant difference between placebo and EOS789 100mg 
TID (p = 0.028). 
 
Figure 5. Example of assessment of intestinal fractional P absorption using a single isotope.  
33P was used to assess fractional P absorption.  Staggering the oral and IV 33P istotpe administration 
by one day allows for the use of this single low energy beta-emitter isotope.  Kinetic modeling of the 
33P radioactivity counts by liquid scintillation counting of plasma samples allows for calculation of 
intestinal fractional P absorption.  DPM = disintegrations per minute. 
  






